The Azole Resistance Crisis Driving a New Antifungal Pipeline

Azole resistance in Aspergillus fumigatus and Candida species has transformed invasive fungal disease from a manageable complication into a therapeutic emergency. Mortality in azole-resistant invasive aspergillosis exceeds 50% in many cohort studies—a figure that has remained stubbornly high despite decades of triazole development—because the dominant resistance mechanism, CYP51A promoter tandem-repeat mutations such as TR34/L98H and TR46/Y121F/T289A, confers cross-resistance to voriconazole, itraconazole, and posaconazole simultaneously, eliminating the entire azole class at a stroke.

The environmental route of resistance acquisition compounds the clinical problem. A. fumigatus spores exposed to azole fungicides used in agriculture acquire CYP51A mutations in the environment, meaning patients can inhale already-resistant conidia without any prior antifungal exposure. According to WHO‘s 2022 fungal priority pathogens list, A. fumigatus and Candida auris are classified as critical-priority pathogens, reflecting the convergence of high mortality, rising resistance, and limited treatment alternatives.

Within the Candida genus, the picture is equally complex. Candida auris—an emerging multidrug-resistant species first described in 2009—is frequently resistant to azoles, often to echinocandins, and occasionally to polyenes, leaving clinicians with no reliable oral option. For Candida glabrata and Candida tropicalis, azole minimum inhibitory concentrations have crept upward across successive surveillance periods, tracked by organisations including ECDC and the CDC. This convergence of resistance across both Aspergillus and Candida is the commercial and scientific rationale that has finally propelled two genuinely new mechanistic classes into late-stage clinical development and, in olorofim’s case, regulatory approval.

Olorofim: A DHODH Inhibitor That Sidesteps the Ergosterol Pathway

Olorofim (F901318, developed by F2G Ltd) acts by inhibiting dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme that catalyses the fourth step of the de novo pyrimidine biosynthesis pathway. Because fungi cannot salvage exogenous pyrimidines efficiently, blocking DHODH is fungicidal in susceptible species. Critically, this target is entirely absent from the ergosterol biosynthesis pathway that azoles, polyenes, and echinocandins all depend upon, meaning azole-resistant A. fumigatus strains—regardless of which CYP51A mutation they carry—retain full susceptibility to olorofim.

The clinical significance of this orthogonal mechanism was confirmed in the FORMULA-OLS study (NCT03583164), a Phase 2/3 open-label trial in patients with invasive mould infections who had failed or were intolerant of standard therapy. Among patients with azole-resistant A. fumigatus infections, olorofim achieved meaningful clinical responses in a population with historically dismal outcomes. Olorofim received FDA approval in June 2024 for the treatment of invasive aspergillosis in adults refractory to or intolerant of standard antifungal therapy—making it the first DHODH inhibitor approved as an antifungal agent anywhere in the world.

Beyond azole-resistant aspergillosis, olorofim’s spectrum extends to other difficult-to-treat hyalohyphomycetes including Lomentospora prolificans and Scedosporium species—organisms for which no licensed therapy previously existed. This positions olorofim as a potential backbone agent for combination regimens targeting pan-resistant mould infections, a space that the PatSnap innovation intelligence platform has tracked as one of the fastest-growing patent filing clusters in antifungal drug discovery since 2020.

“Olorofim is the first antifungal to reach approval with a mechanism entirely outside the ergosterol and cell-wall synthesis paradigms—its DHODH target means azole resistance is simply irrelevant to its activity.”

Ibrexafungerp: First Oral Triterpenoid Glucan Synthase Inhibitor

Ibrexafungerp (SCY-078, developed by SCYNEXIS Inc.) is a first-in-class triterpenoid antifungal that inhibits β-1,3-glucan synthase—the same molecular target as the echinocandin class (caspofungin, micafungin, anidulafungin)—but through a chemically distinct scaffold derived from enfumafungin, a natural triterpenoid. This structural divergence is the key to ibrexafungerp’s clinical differentiation: unlike echinocandins, which are large lipopeptide molecules with negligible oral bioavailability, ibrexafungerp achieves therapeutically relevant plasma concentrations after oral dosing.

Ibrexafungerp received FDA approval in June 2021 for vulvovaginal candidiasis (under the brand name Brexafemme) and a subsequent approval in 2022 for recurrent vulvovaginal candidiasis. Its spectrum covers Candida albicans, Candida glabrata, Candida tropicalis, and critically Candida auris. The activity against C. auris is particularly significant given that this species is frequently resistant to azoles, often to echinocandins (via FKS1 and FKS2 mutations), and sometimes to amphotericin B, leaving clinicians with no reliable oral option prior to ibrexafungerp’s approval.

The triterpenoid scaffold also confers a distinct binding mode on β-1,3-glucan synthase compared with echinocandins, which has been proposed as the mechanistic basis for ibrexafungerp’s retained activity against some FKS-mutant strains—though the degree of cross-resistance with echinocandins remains an active area of investigation. Surveillance data from the SENTRY Antimicrobial Surveillance Program and CDC tracking of C. auris outbreaks have consistently demonstrated ibrexafungerp MICs below the epidemiological cut-off for clinical isolates that are resistant to fluconazole and even to echinocandins.

Mechanism Comparison and Resistance Profiles: Where Each Agent Fits

Olorofim and ibrexafungerp are not competing for the same clinical niche—their mechanisms, spectra, and resistance profiles place them in complementary positions within the antifungal pipeline. Olorofim’s DHODH target makes it the agent of choice for azole-resistant and azole-refractory Aspergillus infections, including those caused by rare moulds such as Lomentospora prolificans for which ibrexafungerp has no meaningful activity. Ibrexafungerp’s glucan synthase inhibition, by contrast, is optimised for Candida infections—particularly where azole resistance or the need for oral step-down therapy is the driving concern.

Resistance potential: early signals from each class

For olorofim, in vitro resistance selection experiments have identified mutations in the DHODH gene (UMPS, pyrE locus) that reduce susceptibility, but clinical resistance has not yet been documented in the post-approval period. The fitness cost of DHODH mutations in a pyrimidine-auxotrophic environment may constrain the emergence of clinically relevant resistance. For ibrexafungerp, FKS mutations that confer echinocandin resistance do not fully cross-protect against ibrexafungerp in all strains—particularly in C. albicans—though elevated MICs have been observed in some FKS1 hot-spot 1 mutants of C. glabrata.

Combination potential

Preclinical data suggest that combining olorofim with azoles or with ibrexafungerp may produce additive to synergistic effects against resistant Aspergillus and Candida isolates. The rationale for olorofim plus azole combinations is that even sub-inhibitory azole concentrations may disrupt ergosterol homeostasis in ways that sensitise cells to pyrimidine starvation. For olorofim plus ibrexafungerp, the dual attack on two entirely distinct essential pathways provides a pharmacological basis for synergy, though robust clinical combination trial data remain limited as of mid-2025.

Pipeline Implications for IP Strategy and R&D Prioritisation

The approval of olorofim and the expanding label of ibrexafungerp signal a structural shift in the antifungal IP landscape. For the first time in over two decades, patent filings in antifungal drug discovery are clustering around mechanistically novel targets rather than around incremental modifications to existing azole or echinocandin scaffolds. According to data tracked through the PatSnap life sciences intelligence platform, DHODH inhibitor patent families in antifungal applications have grown significantly since F2G’s foundational filings, with new entrants exploring DHODH selectivity, prodrug formulations, and spectrum extension to dimorphic fungi.

For ibrexafungerp, the triterpenoid scaffold has attracted follow-on chemistry programmes seeking to improve upon SCYNEXIS’s enfumafungin-derived lead. Patent activity around novel triterpenoid antifungals—including analogues with improved FKS-mutant coverage and extended half-lives—has accelerated since ibrexafungerp’s 2021 approval, reflecting the commercial validation of the oral glucan synthase inhibitor concept. Organisations including NIH‘s National Institute of Allergy and Infectious Diseases (NIAID) have funded preclinical programmes exploring second-generation triterpenoid antifungals with improved pharmacokinetics and broader Candida auris coverage.

What the pipeline still needs

Despite these advances, significant unmet needs remain. Neither olorofim nor ibrexafungerp covers the full spectrum of clinically relevant fungal pathogens. Olorofim lacks meaningful activity against Candida species and mucormycetes; ibrexafungerp has limited activity against Aspergillus and no activity against Cryptococcus neoformans. The next frontier for oral antifungal development—as catalogued in WHO‘s fungal priority pathogen framework—includes agents active against mucormycetes, Cryptococcus, and pan-resistant Candida auris with FKS mutations that reduce ibrexafungerp susceptibility.

• Olorofim gaps: No activity against Candida species, mucormycetes, or Cryptococcus neoformans.
• Ibrexafungerp gaps: Limited Aspergillus activity; elevated MICs in some FKS-mutant C. glabrata strains; no Cryptococcus coverage.
• Shared opportunity: Combination regimens pairing DHODH inhibition with glucan synthase inhibition represent an unexplored clinical strategy with preclinical synergy data.
• IP white space: DHODH inhibitors active against dimorphic fungi (Histoplasma, Coccidioides) and mucormycetes remain an open patent landscape.

For R&D teams and IP strategists, the practical takeaway is that the antifungal pipeline is no longer a single-lane road dominated by azole chemistry. The approval of two mechanistically distinct oral agents within three years has validated two entirely new target classes, created commercial benchmarks for oral bioavailability from non-azole scaffolds, and opened patent white space in DHODH selectivity, triterpenoid second-generation chemistry, and combination product formulations. Teams using innovation intelligence tools can now map these white spaces with precision—identifying which assignees hold foundational patents, where continuation filings are clustering, and which clinical-stage programmes are approaching the freedom-to-operate boundaries established by F2G and SCYNEXIS.